CD8A and non-small cell lung carcinoma: In another study of 29 advanced NSCLC patients treated with anti-PD1 inhibitors, an increase in the proliferation of PD1+ CD8+ T cells levels was observed in responders within the first two cycles of immunotherapy [117].